scispace - formally typeset
S

Sergio Ricci

Researcher at University of Pisa

Publications -  87
Citations -  17024

Sergio Ricci is an academic researcher from University of Pisa. The author has contributed to research in topics: Sorafenib & Cancer. The author has an hindex of 28, co-authored 87 publications receiving 14757 citations. Previous affiliations of Sergio Ricci include Bayer.

Papers
More filters

Alpha-2B-Interferon Plus Floxuridine in Metastatic Renal Cell Carcinoma

TL;DR: In this article, the maximum tolerable dose (MTD) of floxuridine (FUDR), administered as a constant continuous infusion for 14 days every 28 days, in combination with fixed doses of alpha-2B-interferon and to preliminarily evaluate the antitumor activity of this combination.
Journal ArticleDOI

A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial

TL;DR: The safety and efficacy data suggest that the association So + IL-2 is safe and feasible and, compared to So alone, improves tumour shrinkage, disease control rate and PFS.
Journal ArticleDOI

Effectiveness of Multi-Prognostic Index in older patients with advanced malignancies treated with immunotherapy.

TL;DR: It is found that the Multi-Prognostic Index score is an effective tool for the stratification of older patients with cancer eligible for immunotherapy with checkpoint inhibitors and further studies are required to achieve conclusive remarks on MPI usefulness in different underlying tumor types.
Journal ArticleDOI

Gastrointestinal tumors, non-colorectal

Mitesh J. Borad, +759 more
- 01 Sep 2012 - 
TL;DR: The combination of G plus TH-302 improved the efficacy of G and skin and mucosal toxicity and myelosuppression were the most common TH- 302 related AEs with no increase in treatment discontinuation.